| Literature DB >> 28420649 |
Nicolai J Wewer Albrechtsen1,2, Ali Asmar3, Frederik Jensen1,2, Signe Törang1,2, Lene Simonsen3, Rune E Kuhre1,2, Meena Asmar3, Simon Veedfald1,2, Astrid Plamboeck1,2, Filip K Knop2,4,5, Tina Vilsbøll4,5,6, Sten Madsbad7, Michael A Nauck8, Carolyn F Deacon1,2, Jens Bülow3, Jens J Holst9,2, Bolette Hartmann1,2.
Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from the gastrointestinal tract. It is best known for its glucose-dependent insulinotropic effects. GLP-1 is secreted in its intact (active) form (7-36NH2) but is rapidly degraded by the dipeptidyl peptidase 4 (DPP-4) enzyme, converting >90% to the primary metabolite (9-36NH2) before reaching the targets via the circulation. Although originally thought to be inactive or antagonistic, GLP-1 9-36NH2 may have independent actions, and it is therefore relevant to be able to measure it. Because reliable assays were not available, we developed a sandwich ELISA recognizing both GLP-1 9-36NH2 and nonamidated GLP-1 9-37. The ELISA was validated using analytical assay validation guidelines and by comparing it to a subtraction-based method, hitherto employed for estimation of GLP-1 9-36NH2 Its accuracy was evaluated from measurements of plasma obtained during intravenous infusions (1.5 pmol × kg-1 × min-1) of GLP-1 7-36NH2 in healthy subjects and patients with type 2 diabetes. Plasma levels of the endogenous GLP-1 metabolite increased during a meal challenge in patients with type 2 diabetes, and treatment with a DPP-4 inhibitor fully blocked its formation. Accurate measurements of the GLP-1 metabolite may contribute to understanding its physiology and role of GLP-1 in diabetes.Entities:
Keywords: DPP-4; ELISA; GLP-1; GLP-1 metabolite; diabetes
Mesh:
Substances:
Year: 2017 PMID: 28420649 DOI: 10.1152/ajpendo.00005.2017
Source DB: PubMed Journal: Am J Physiol Endocrinol Metab ISSN: 0193-1849 Impact factor: 4.310